Vera Therapeutics shares saw a notable increase ahead of an anticipated decision from the U.S. FDA. Meanwhile, Steel Partners made a proposal to acquire InMode for $16.75 per share. Additionally, Greenwich LifeSciences shares rose following approval from the European Medicines Agency regarding its experimental drug GP2.
